Delivering on genetic medicines
Aera’s mission is to unlock the potential of genetic medicines by tacking the greatest unmet need in the field today – delivery. Aera has multiple proprietary delivery platforms including targeted lipid nanoparticles (tLNPs), antibody oligonucleotide conjugates (AOCs), and protein nanoparticles (PNPs), that are being developed to enable next-generation genetic medicines across a range of therapeutic modalities and disease areas.
These platforms have the potential to overcome the limitations of today’s delivery technologies and expand the application of genetic medicines.
